Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA says Maven spacecraft that was orbiting Mars has gone silent - 2The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- 3Step by step instructions to Protect Your Retirement with Senior Protection.
- 4Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
- 5Vote in favor of your Number one natural product
- April's full moon decides the date of Easter — here's how it works
- Nature: 10 High priority Setting up camp Spots In Europe
- Becoming the best at Discussion: Individual Procedures
- The Main 20 Gaming Control center Ever
- The 15 Most Powerful Forerunners in Business
- Passenger Missing After Going Overboard Disney Cruise Ship
- Astronauts head home early after medical issue
- Every year, she thanks the trooper for the arrest that led to her sobriety
- Key Little Things That Advantage Old People
